Mrp2

Constitutive Knock Out

Mrp2 Constitutive Knock Out Mouse Model
EZcohort™ Models
The easiest way to acquire and breed cryopreserved GEMs
LEARN MORE or INQUIRE

FVB Background

  • Model #
  • Genotype
  • Nomenclature
  • 6621-F
    ko/ko
    FVB.129P2-Abcc2tm1AhsN7
  • 6621-M
    ko/ko
    FVB.129P2-Abcc2tm1AhsN7
  • This targeted mutation strain carries a disruption of the Abcc2 gene that encodes multidrug resistance protein 2
  • Useful for the examination of compound uptake and elimination mechanisms
  • Useful for studies on drug resistance in tumors
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:

FVB Background

Origin:

The Mrp2 mouse was developed in the laboratory of Alfred Schinkel of the Netherlands Cancer Institute. The model was created through targeting of the Abcc2 gene in 129/Ola-derived E14 ES cells and injecting the targeted cells into C57BL/6 blastocysts. Resultant chimeras were backcrossed to FVB/N for seven generations (N7). Taconic received stock in 2006, and the line was embryo transfer derived. The colony is maintained by mating homozygotes.

Genetics:

Wild type for Nnt mutation; carries Pde6brd1 mutation

Color:

Albino

Species:

Mouse

Initial Publication:

  • Vlaming MLH, Mohrmann K, Wagenaar E, de Waart DR, Oude Elferink RPJ, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JHM, Schinkel AH. (2006) Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318(1):319-327
Additional Publication:
  • van Waterschoot RAB, ter Heine R, Waagenar E, van der Kruijssen CMM, Rooswinkel RW, Huitema ADR, Beijnen JH, Schinkel AH (2010). Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 160(5):1224-1233.


Conditions of Use for EZcohort™ Models
EZcohort™ models are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic Biosciences, Inc. (Taconic) sells EZcohort™ models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased EZcohort™ models in consideration of purchasers' acknowledgement of and agreement to Taconic's Terms and Conditions for the Sale of Products and the following conditions of use:

  • Title to EZcohort™ models and biological materials derived from them remains with Taconic.
  • EZcohort™ models will be used for research purposes only.
  • EZcohort™ models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
  • Breeders from deliverables can be used for propagation of EZcohort™ models or to cross to other strains.
  • Continuation of breeding and crossbreeding of EZcohort™ models outside Taconicis permitted for a term of three years post-purchase of the EZcohort™ models and is subject to annual confirmation of these EZcohort™ Conditions of Use.

Continuation of breeding and crossbreeding after the three year term will require renewal of the EZcohort™ Conditions of Use and payment of a fee.